drugset
Drugs / sac-TMT
last change May 2026 re-read 3 minutes ago

sac-TMT

Developed for
non-small cell lung carcinoma
Investigated by
Merck Sharp & Dohme LLC

Trials 1

today NCT06422143 · Ph 3
20252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06422143 Jun 2024 → Jan 2029 expected non-small cell lung carcinoma Merck Sharp & Dohme LLC Recruiting No outcome recorded

Press releases naming this drug 6 releases

DateIssuerRelease
2026-05-18 Merck Sharp & Dohme LLC Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer merck.com ↗
2025-11-04 Merck Sharp & Dohme LLC MSD Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) msd.com ↗
2025-11-04 Merck Sharp & Dohme LLC Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) merck.com ↗
2024-12-03 Merck Sharp & Dohme LLC FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations merck.com ↗
2024-05-24 Klus Pharma Inc. Two Abstracts of SKB264/sac-TMT (TROP2 ADC) published at 2024 ASCO Annual Meeting kluspharma.com ↗
2024-05-24 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ASCO 2024| Two Abstracts of the Study Results of Kelun-Biotech’s TROP2-ADC SKB264/sac-TMT Published Today–OptiTROP-Breast01 study AND the OptiTROP-Lung01 study kelun-biotech.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as sac-TMT ClinicalTrials.gov intervention name — accepted as the source's own label NCT06422143 ↗
Route Intravenous “IV infusion” NCT06422143 ↗